SVB Wealth LLC Has $5.41 Million Stock Holdings in Elevance Health, Inc. $ELV

SVB Wealth LLC cut its holdings in Elevance Health, Inc. (NYSE:ELV) by 19.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 16,749 shares of the company’s stock after selling 4,116 shares during the quarter. SVB Wealth LLC’s holdings in Elevance Health were worth $5,412,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in ELV. Nilsine Partners LLC lifted its position in Elevance Health by 1.5% during the third quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock worth $620,000 after purchasing an additional 29 shares during the period. HBK Sorce Advisory LLC lifted its stake in shares of Elevance Health by 4.4% in the 3rd quarter. HBK Sorce Advisory LLC now owns 743 shares of the company’s stock valued at $260,000 after acquiring an additional 31 shares during the last quarter. Detalus Advisors LLC raised its position in Elevance Health by 1.8% in the third quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock valued at $558,000 after purchasing an additional 31 shares during the last quarter. Forum Financial Management LP raised its holdings in Elevance Health by 1.1% in the 3rd quarter. Forum Financial Management LP now owns 2,971 shares of the company’s stock valued at $960,000 after buying an additional 33 shares during the last quarter. Finally, Activest Wealth Management raised its stake in shares of Elevance Health by 66.7% during the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after acquiring an additional 34 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Price Performance

Shares of NYSE ELV opened at $326.44 on Tuesday. The stock has a fifty day simple moving average of $351.97 and a two-hundred day simple moving average of $331.02. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75. The firm has a market cap of $72.55 billion, a price-to-earnings ratio of 13.00, a price-to-earnings-growth ratio of 1.89 and a beta of 0.50. The company has a current ratio of 1.54, a quick ratio of 1.56 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last released its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.10 by $0.23. The business had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The company’s revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Analysts anticipate that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be issued a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, March 10th. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s payout ratio is presently 27.23%.

Wall Street Analyst Weigh In

ELV has been the subject of a number of analyst reports. Truist Financial lowered their price objective on Elevance Health from $400.00 to $390.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Leerink Partners lifted their price target on shares of Elevance Health from $350.00 to $357.00 and gave the company a “market perform” rating in a research note on Thursday, January 29th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $332.00 price objective on shares of Elevance Health in a report on Thursday, January 29th. Morgan Stanley decreased their target price on shares of Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 17th. Finally, TD Cowen reissued a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. Twelve equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $390.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.